Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial

Author:

Newman Jonathan D.1,Alexander Karen P.2,Gu Xiangqiong2,O’Brien Sean M.2,Boden William E.3,Govindan Sajeev C.4,Senior Roxy5,Moorthy Nagaraja6,Rezende Paulo C.7,Demkow Marcin8,Lopez-Sendon Jose Luis9,Bockeria Olga10,Pandit Neeraj11,Gosselin Gilbert12,Stone Peter H.13,Spertus John A.14,Stone Gregg W.15,Fleg Jerome L.16,Hochman Judith S.1,Maron David J.17,

Affiliation:

1. New York University School of Medicine (J.D.N., J.S.H.).

2. Duke Clinical Research Institute, Durham, NC (K.P.A., X.G., S.M.O.).

3. VA New England Healthcare System, Boston, MA (W.E.B.).

4. Government Medical College, Kerala, India (S.C.G.).

5. Northwick Park Hospital-Royal Brompton Hospital, London, United Kingdom (R.S.).

6. Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India (N.M.).

7. Heart Instituto do Coracao, University of Sao Paulo, Brazil (P.C.R.).

8. Coronary and Structural Heart Diseases Department, Institute of Cardiology, Warsaw, Poland (M.D.).

9. Hospital Universitario La Paz, Idipaz, Madrid, Spain (J.L.L.-S.).

10. National Research Center for Cardiovascular Surgery, Moscow, Russia (O.B.).

11. Ram Manohar Lohia Hospital, Delhi, India (N.P.).

12. Montreal Heart Institute, QC, Canada (G.G.).

13. Brigham and Women’s Hospital, MA (P.H.S.).

14. Saint Luke’s Mid America Heart Institute/UMKC, MO (J.A.S.).

15. Columbia University Medical Center and the Cardiovascular Research Foundation, NY (J.W.S.).

16. National Institute of Health, NHLBI, MD (J.L.F.).

17. Stanford University School of Medicine, CA (D.J.M.).

Abstract

Background: Risk factor control is the cornerstone of managing stable ischemic heart disease but is often not achieved. Predictors of risk factor control in a randomized clinical trial have not been described. Methods and Results: The ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) randomized individuals with at least moderate inducible ischemia and obstructive coronary artery disease to an initial invasive or conservative strategy in addition to optimal medical therapy. The primary aim of this analysis was to determine predictors of meeting trial goals for LDL-C (low-density lipoprotein cholesterol, goal <70 mg/dL) or systolic blood pressure (SBP, goal <140 mm Hg) at 1 year post-randomization. We included all randomized participants in the ISCHEMIA trial with baseline and 1-year LDL-C and SBP values by January 28, 2019. Among the 3984 ISCHEMIA participants (78% of 5179 randomized) with available data, 35% were at goal for LDL-C, and 65% were at goal for SBP at baseline. At 1 year, the percent at goal increased to 52% for LDL-C and 75% for SBP. Adjusted odds of 1-year LDL-C goal attainment were greater with older age (odds ratio [OR], 1.11 [95% CI, 1.03–1.20] per 10 years), lower baseline LDL-C (OR, 1.19 [95% CI, 1.17–1.22] per 10 mg/dL), high-intensity statin use (OR, 1.30 [95% CI, 1.12–1.51]), nonwhite race (OR, 1.32 [95% CI, 1.07–1.63]), and North American enrollment compared with other regions (OR, 1.32 [95% CI, 1.06–1.66]). Women were less likely than men to achieve 1-year LDL-C goal (OR, 0.68 [95% CI, 0.58–0.80]). Adjusted odds of 1-year SBP goal attainment were greater with lower baseline SBP (OR, 1.27 [95% CI, 1.22–1.33] per 10 mm Hg) and with North American enrollment (OR, 1.35 [95% CI, 1.04–1.76]). Conclusions: In ISCHEMIA, older age, male sex, high-intensity statin use, lower baseline LDL-C, and North American location predicted 1-year LDL-C goal attainment, whereas lower baseline SBP and North American location predicted 1-year SBP goal attainment. Future studies should examine the effects of sex disparities, international practice patterns, and provider behavior on risk factor control.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3